Anagrelide ๐
โ ๏ธ For expert haematology use only
Always verify dosing and monitoring via the BNF entry for Anagrelide.
๐ About
- Selective platelet-lowering agent used under specialist supervision.
- Refer to the BNF or institutional guidelines for up-to-date prescribing advice.
โ๏ธ Mode of Action
- Exact mechanism remains incompletely understood.
- Inhibits cyclic AMP phosphodiesterase type III (PDE-III) โ reduces megakaryocyte maturation and platelet production.
๐ Indications & Dose
| Name |
Typical Dose |
Frequency |
Route |
| Anagrelide (for Essential Thrombocythaemia or CML-associated thrombocytosis) |
Start at 500 micrograms BD. Titrate gradually to usual dose 1โ3 mg/day in divided doses.
Max per dose 2.5 mg; max daily 10 mg. |
BDโTDS |
Oral |
๐ Interactions
- Avoid concurrent use with other PDE-III inhibitors (e.g. milrinone, cilostazol, enoximone).
- Use caution with anticoagulants or antiplatelet agents (โ bleeding risk).
โ ๏ธ Cautions
- Monitor FBC, U&E, and LFTs regularly during treatment.
- Assess QTc interval; avoid if prolonged or in significant cardiac disease.
- Use with care in renal impairment or heart failure.
๐ซ Contraindications
- Moderate to severe hepatic impairment.
- Pregnancy and breastfeeding.
๐ฅ Side Effects
- Haematological: Thrombocytopenia, anaemia.
- Cardiac: Palpitations, tachycardia, arrhythmias, heart failure.
- GI: Nausea, diarrhoea, abdominal pain.
- Other: Headache, dizziness, oedema, dyspnoea, rare interstitial lung disease.
๐ References